Literature DB >> 7872754

Activity of WY-49605 compared with those of amoxicillin, amoxicillin-clavulanate, imipenem, ciprofloxacin, cefaclor, cefpodoxime, cefuroxime, clindamycin, and metronidazole against 384 anaerobic bacteria.

S K Spangler1, M R Jacobs, P C Appelbaum.   

Abstract

The National Committee for Clinical Laboratory Standards agar dilution method was used to compare the in vitro activity of WY-49605 (also called SUN/SY 5555 and ALP-201), a new broad-spectrum oral penem, to those of amoxicillin, amoxicillin-clavulanate, imipenem, ciprofloxacin, cefaclor, cefpodoxime, cefuroxime, clindamycin, and metronidazole against 384 clinically isolated anaerobes. These anaerobic organisms included 90 strains from the Bacteroides fragilis group, 87 Prevotella and Porphyromonas strains, non-B. fragilis group Bacteroides strains, 56 fusobacteria, 55 peptostreptococci, 49 gram-positive non-spore-forming rods, and 47 clostridia. Overall, WY-49605 had an MIC range of 0.015 to 8.0 micrograms/ml, an MIC at which 50% of the isolates are inhibited (MIC50) of 0.25 microgram/ml, and an MIC at which 90% of the isolates are inhibited (MIC90) of 2.0 micrograms/ml. Good activity against all anaerobe groups was observed, except for Clostridium difficile and lactobacilli (MIC50s of 4.0 and 2.0 micrograms/ml, respectively, and MIC90s of 8.0 and 2.0 micrograms/ml, respectively). Imipenem had an MIC50 of 0.03 microgram/ml and an MIC90 of 0.25 microgram/ml. Ciprofloxacin was much less active (MIC50 of 2.0 micrograms/ml and MIC90 of 16.0 micrograms/ml). By comparison, all oral beta-lactams were less active than WY-49605, with susceptibilities as follows: amoxicillin MIC50 of 8.0 micrograms/ml and MIC90 of > 256.0 micrograms/ml), amoxicillin-clavulanate MIC50 of 1.0 microgram/ml and MIC90 of 8.0 micrograms/ml, cefaclor MIC50 of 8.0 micrograms/ml and MIC90 of > 32.0 micrograms/ml, cefpodoxime MIC50 of 4.0 micrograms/ml and MIC90 of > 32.0 micrograms/ml, and cefuroxime MIC50 of 4.0 micrograms/ml and MIC90 of > 32.0 micrograms/ml. Clindamycin was active against all groups except some members of the B. fragilis group, Fusobacterium varium, and some clostridia ( overall MIC50 of 0.5 micrograms/ml and overall MIC90 of 8.0 micrograms/ml). Metronidazole was active (MIC of less than or equal to 4.0 micrograms/ml) against all gram-negative anaerobic rods, but most gram-positive non-spore-forming rods, some peptostreptococci, and some clostridia were less susceptible. To date, WY-49605 is the most active oral beta-lactam against anaerobes: these results suggest clinical evaluation for clinical indications suitable for oral therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7872754      PMCID: PMC188248          DOI: 10.1128/AAC.38.11.2599

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Studies on penem antibiotics. II. In vitro activity of SUN5555, a new oral penem.

Authors:  T Nishino; Y Maeda; E Ohtsu; S Koizuka; T Nishihara; H Adachi; K Okamoto; M Ishiguro
Journal:  J Antibiot (Tokyo)       Date:  1989-06       Impact factor: 2.649

2.  Characterization of beta-lactamases from non-Bacteroides fragilis group Bacteroides spp. belonging to seven species and their role in beta-lactam resistance.

Authors:  P C Appelbaum; A Philippon; M R Jacobs; S K Spangler; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

3.  Susceptibility of anaerobic bacteria to ALP 201.

Authors:  C E Nord; A Lindmark; I Persson
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

4.  Comparative in vitro activity of the new oral penem ALP-201 against aerobic and anaerobic bacteria.

Authors:  M Rylander; C E Nord; S R Norrby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

5.  Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers.

Authors:  P C Appelbaum; S K Spangler; M R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

6.  Beta-lactamase production, beta-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres.

Authors:  M R Jacobs; S K Spangler; P C Appelbaum
Journal:  J Antimicrob Chemother       Date:  1990-09       Impact factor: 5.790

7.  Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.

Authors:  P C Appelbaum; S K Spangler; M R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

Review 8.  Mechanisms of beta-lactam resistance in anaerobic bacteria.

Authors:  C E Nord
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

9.  Characterization of a beta-lactamase from Clostridium clostridioforme.

Authors:  P C Appelbaum; S K Spangler; G A Pankuch; A Philippon; M R Jacobs; R Shiman; E J Goldstein; D M Citron
Journal:  J Antimicrob Chemother       Date:  1994-01       Impact factor: 5.790

10.  Evaluation of two methods for rapid testing for beta-lactamase production in Bacteroides and Fusobacterium.

Authors:  P C Appelbaum; S K Spangler; M R Jacobs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-01       Impact factor: 3.267

View more
  8 in total

Review 1.  Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.

Authors:  J A Balfour; H M Bryson; R N Brogden
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

2.  Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors:  Ian A Critchley; James A Karlowsky; Deborah C Draghi; Mark E Jones; Clyde Thornsberry; Kate Murfitt; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

3.  In vitro activities of faropenem against 579 strains of anaerobic bacteria.

Authors:  Hannah M Wexler; Denise Molitoris; Shahera St John; Ann Vu; Erik K Read; Sydney M Finegold
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

Review 4.  Taxonomy, biology, and periodontal aspects of Fusobacterium nucleatum.

Authors:  A I Bolstad; H B Jensen; V Bakken
Journal:  Clin Microbiol Rev       Date:  1996-01       Impact factor: 26.132

5.  Identification and antimicrobial resistance patterns of clinical isolates of Clostridium clostridioforme, Clostridium innocuum, and Clostridium ramosum compared with those of clinical isolates of Clostridium perfringens.

Authors:  C J Alexander; D M Citron; J S Brazier; E J Goldstein
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

Review 6.  Clostridium innocuum: Microbiological and clinical characteristics of a potential emerging pathogen.

Authors:  Kathryn E Cherny; Emily B Muscat; Megan E Reyna; Larry K Kociolek
Journal:  Anaerobe       Date:  2021-07-28       Impact factor: 3.331

Review 7.  Role of cephalosporins in the era of Clostridium difficile infection.

Authors:  Mark H Wilcox; James D Chalmers; Carl E Nord; Jane Freeman; Emilio Bouza
Journal:  J Antimicrob Chemother       Date:  2016-09-22       Impact factor: 5.790

8.  High Abundance of Proteobacteria in Ileo-Anal Pouch Anastomosis and Increased Abundance of Fusobacteria Associated with Increased Pouch Inflammation.

Authors:  Andreas Munk Petersen; Hengameh Chloé Mirsepasi-Lauridsen; Marianne K Vester-Andersen; Nikolaj Sørensen; Karen Angeliki Krogfelt; Flemming Bendtsen
Journal:  Antibiotics (Basel)       Date:  2020-05-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.